Singular Genomics Systems Stock Analysis

Singular Stock Analysis Notes

About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Singular Genomics Systems recorded a loss per share of 34.68. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 26th of June 2024. Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California. Singular Genomics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 248 people. To find out more about Singular Genomics Systems contact Andrew Spaventa at 858 333 7830 or learn more at https://www.singulargenomics.com.

Singular Genomics Systems Investment Alerts

Singular Genomics Systems Upcoming and Recent Events

Singular Largest EPS Surprises

View All Earnings Estimates

Singular Genomics Environmental, Social, and Governance (ESG) Scores

Singular Genomics Thematic Classifications

Singular Stock Institutional Investors

Note, although Singular Genomics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Singular Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 54.77 M.

Singular Profitablity

Management Efficiency

Singular Genomics Systems has return on total asset (ROA) of (0.2427) % which means that it has lost $0.2427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5161) %, meaning that it created substantial loss on money invested by shareholders. Singular Genomics' management efficiency ratios could be used to measure how well Singular Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.44. At present, Singular Genomics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.2 M, whereas Total Assets are forecasted to decline to about 226.1 M.

Technical Drivers

As of the 30th of November, Singular Genomics has the Semi Deviation of 2.78, coefficient of variation of 627.69, and Risk Adjusted Performance of 0.1313. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Singular Genomics Systems, as well as the relationship between them.

Singular Genomics Systems Price Movement Analysis

Singular Genomics Systems Insider Trading Activities

Singular Genomics Outstanding Bonds

Singular Genomics Predictive Daily Indicators

Singular Genomics Corporate Filings

Singular Genomics Forecast Models

Singular Genomics' time-series forecasting models are one of many Singular Genomics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Singular Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Singular Genomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Singular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Singular Genomics. By using and applying Singular Stock analysis, traders can create a robust methodology for identifying Singular entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Singular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Singular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Singular Genomics Systems stock analysis indicators help investors evaluate how Singular Genomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Singular Genomics shares will generate the highest return on investment. By understating and applying Singular Genomics stock analysis, traders can identify Singular Genomics position entry and exit signals to maximize returns.

When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.